▲ +280.62% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for G1 Therapeutics in the last 3 months. The average price target is $54.43, with a high forecast of $82.00 and a low forecast of $21.00. The average price target represents a 280.62% upside from the last price of $14.30.
The current consensus among 8 investment analysts is to buy stock in G1 Therapeutics. This Buy consensus rating has held steady for over two years.
G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. It is developing trilaciclib, an intravenous cyclin-dependent kinases (CDK) 4/6 inhibitor that is in Phase 1b/2 clinical trials for patients with extensive-stage small cell lung cancer(SCLC), as well as Phase 2 clinical trial for patients with first-line (SCLC) and metastatic triple-negative breast cancer; lerociclib, an oral CDK4/6 inhibitor that is in Phase 1b/2a clinical trials for the treatment of breast cancer and in Phase 1b clinical trial for non-small cell lung cancer; and rintodestrant, an oral selective estrogen receptor degrader, which is in Phase I/2 clinical trial. G1 Therapeutics, Inc. has a collaboration with Quantum Leap Healthcare Collaborative to evaluate trilaciclib for neoadjuvant treatment of locally advanced breast cancer. The company was founded in 2008 and is headquartered in Research Triangle Park, North Carolina.